V-Prevent

In Follow Up, Cholesterol
The purpose of this study is to evaluate inclisiran sodium 300 mg s.c. (equivalent to 284 mg inclisiran) compared to placebo on reducing the…

Oceanic (a)

In Follow Up, Lipoprotein (a)
The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease…

Alpaca

In Follow Up, Lipoprotein (a)
The main purpose of this study is to determine the efficacy and safety of LY3819469 in adults with elevated lipoprotein(a). The study will…

Surmount-MMO

In Follow Up, Weight Loss
This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide…

Azalea A Fib

In Follow Up
The purpose of the ANT-006 study is to evaluate the bleeding profile of abelacimab relative to rivaroxaban in patients with atrial…

Summit

Heart Failure, In Follow Up
The main purpose of this study is to assess the efficacy and safety of Tirzepatide (LY3298176) in participants with heart failure with…

Arrowhead

In Follow Up, High Triglyceride
The purpose of AROANG3-2001 is to evaluate the efficacy and safety of ARO-ANG3 in participants with mixed dyslipidemia. Participants will…

Stride

In Follow Up, Leg Pain/disease
The primary objective of this study is to collect safety and performance data on the Indigo Aspiration System in a patient population with…

Vesalius-cv

In Follow Up, Cholesterol
This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in…

SURPASS-CVOT

In Follow Up
The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and…

Orion

In Follow Up, Cholesterol
ORION-4 is a research study coordinated by the University of Oxford and co-sponsored by The University of Oxford and Novartis (Protocol…
Capital Area Research LLC © Copyright 2024 All rights reserved.
875 Popular Church Rd. Suite 330 Camp Hill, PA - 717.963.8389